Tardive dyskinesia in a patient treated with quetiapine

World Journal of Biological Psychiatry

Volumn 10, Issue 1, 2009, Pages 54-57

  Rizos, Emmanouil ^a   Douzenis, Athanassios ^a   Gournellis, Rossetos ^a   Christodoulou, Christos ^a   Lykouras, Lefteris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Quetiapine; Schizoaffective disorder; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BIPERIDEN; MIRTAZAPINE; QUETIAPINE; VENLAFAXINE; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; ANAMNESIS; ANXIETY DISORDER; ARTICLE; CASE REPORT; CLINICAL FEATURE; DECREASED APPETITE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FACIAL EXPRESSION; FEMALE; HUMAN; MENTAL FUNCTION; REMISSION; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; TARDIVE DYSKINESIA; TREMOR;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIBENZOTHIAZEPINES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; SULPIRIDE; THIAZOLES;

EID: 61649117336     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701362550     Document Type: Article

References (34)

1. Ananth, J., Burgoyne, KS, Niz, D. and Smith, M. (2004) Tardive dyskinesia in 2 patients treated with ziprasidone. J Psychiatry Neurosci, 29, pp. 467-469.
2. Bakker, RP, van Harten, P. and van Os, J. (2006) Antipsychotic-induced tardive dyskinesia and the ser9Gly polymorphism in the DRD3 gene: A meta analysis. Schizophr Res, 83, pp. 185-192.
3. Bressan, RA, Erlandsson, K., Jones, HM, Mulligan, R., Flanagan, RJ, Ell, PJ and Pilowski, LS (2003) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative <123>epidepride SPET study of amisulpride-treated patients. Am J Psychiatry, 160, pp. 1413-1420.
4. Casey, DE (1995) Tardive dyskinesia. Psychopharmacology, pp. 1497-1501. The American College of Neuropsychopharmacology, Nashville, TN
5. Correl, CU, Leucht, S. and Kane, JM (2004) Lower risk for tardive dyskinesia associated with second generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry, 161, pp. 414-425.
6. Cudennec, A., Fage, D., Benavides, J. and Scatton, B. (1997) Effects of amisoulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain Res, 12, pp. 257-265.
7. Egan, MF, Apud, J. and Wyatt, RJ (1997) Treatment of tardive dyskinesia. Schizophr Bull, 23, pp. 583-609.
8. Emsley, R., Turner, HJ, Schronen, J., Botha, K., Smit, R. and Oosthuizen, PP (2004) single-blind, randomized trial comparing quetiapine and haloperidole in the treatment of tardive dyskinesia. J Clin Psychiatry, 65, pp. 696-701.
9. 2A receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol, 11, pp. 105-110.
10. Ghaemi, SN (2001) Quetiapine-related tardive dyskinesia. Am J Psychiatry, 158, p. 1737.
11. Ghelber, D. and Belmaker, RH (1999) Tardive dyskinesia with quetiapine. Am J Psychiatry, 156, pp. 796-797.
12. Kane, JM (1999) Tardive Dyskinesia in affective disorders. J Clin Psychiatry, 60, pp. 43-47.
13. Kane, JM (2001) Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol, 11, pp. 397-403.
14. Kane, JM (2004) Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence. J Clin Psychiatry, 65, p. S16.
15. Kapur, S. and Seeman, P. (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry, 158, pp. 360-369.
16. Keck, ME, Muller, MB, Binder, EB, Sonntag, A. and Holsboer, F. (2004) Ziprasidone-related tardive dyskinesia. Am J Psychiatry, 161, pp. 175-176.
17. Krebs, MO, Sautel, F. Bourdel, MC et al. (1998) Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry, 4, pp. 337-341.
18. Lerer, B., Segman, RH Fangerau, H. et al. (2002) Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Glypolymorphism. Neuropsychopharmacology, 27:1, pp. 105-119.
19. Llorca, PM, Cherau, I., Bayle, FJ and Lancon, C. (2002) Tardive dyskinesia and antipsychotics: A review. Eur Psychiatry, 17, pp. 129-138.
20. Lykouras, L., Yannakis, R., Hatzimanolis, J. and Christodoulou, GN (1999) Two cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur Psychiatry, 14, pp. 245-247.
21. Mendhekar, DN (2005) Ziprasidone-induced tardive dyskinesia. Can J Psychiatry, 50, pp. 567-568.
22. Nemeroff, CB, Kinkead, B. and Goldstein, I. (2002) Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. J Clin Psychiatry, 63, pp. 5-11.
23. Papapetropoulos, S., Wheeler, S. and Singer, C. (2005) Tardive dystonia associated with ziprasidone. Am J Psychiatry, 162, p. 2191.
24. Rosenquist, KJ, Walker, SS and Ghaemi, SN (2002) Tardive Dyskinesia and ziprasidone. Am J Psychiatry, 159, p. 1436.
25. Saccheti, E. and Valsecchi, P. (2003) Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: A 124-week case report. Int Clin Psychopharmacol, 18, pp. 357-359.
26. Scatton, B., Claustre, Y. Cudennec, A. et al. (1997) Amisoulpride: From animal pharmacology to therapeutic action. Int Clin Psychopgarmacology, 12, p. S29.
27. Schoemaker, H., Claustre, Y. and Fage, D. (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther, 280, pp. 83-97.
28. Segman, R., Neeman, T. Heresco-Levy, U. et al. (1999) Genotyping association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry, 4, pp. 418-428.
29. Sharma, A., Ramaswamy, S. and Dewan, VK (2005) Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry, 7, p. 36.
30. Sharma, V. (2003) Treatment-emergent tardive dyskinesia with quetiapine in Mood Disorders. J Clin Psychopharmacol, 23, pp. 415-416.
31. Srivastava, V., Varma, PG Prasad, S. et al. (2006) Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genom, 16, pp. 111-117.
32. Steen, VM, Lovelie, R., MacEvan, T. and McCreadie, RG. (1997) Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry, 2, pp. 139-145.
33. Stephenson, CM, Bigliani, V. Jones, HM et al. (2000) Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry, 177, pp. 408-415.
34. 2 dopamine receptor blockage by amisulpride in schizophrenia. J Clin Psychopharmacol, 21, pp. 207-214.